CTP amio
Alternative Names: CTP-amioLatest Information Update: 28 Aug 2024
At a glance
- Originator Vivasc Therapeutics
- Developer University of Pittsburgh; Vivasc Therapeutics
- Class Antiarrhythmics; Benzofurans; Peptide drug conjugates
- Mechanism of Action Beta adrenergic receptor antagonists; KATP channel inhibitors; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Atrial fibrillation; Ventricular tachycardia
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for preclinical development in Atrial-fibrillation in USA
- 28 Aug 2024 No recent reports of development identified for preclinical development in Ventricular-tachycardia in USA
- 29 May 2023 Discontinued - Preclinical for Atrial fibrillation in USA (unspecified route), before May 2023 (Vivasc Therapeutics pipeline, May 2023)